Anaphylaxis after zoster vaccine: Implicating alpha-gal allergy as a possible mechanism - 27/09/17
Doi : 10.1016/j.jaci.2016.10.037
Cosby A. Stone, MD, MPH a 
, Jonathan A. Hemler, MD a, Scott P. Commins, MD, PhD b, Alexander J. Schuyler, BS, BA c, Elizabeth J. Phillips, MD d, f, g, h, R. Stokes Peebles, MD a, e, John M. Fahrenholz, MD a, e
, Jonathan A. Hemler, MD a, Scott P. Commins, MD, PhD b, Alexander J. Schuyler, BS, BA c, Elizabeth J. Phillips, MD d, f, g, h, R. Stokes Peebles, MD a, e, John M. Fahrenholz, MD a, e a Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn
d Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn
b Division of Rheumatology, Allergy & Immunology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC
c Asthma and Allergic Disease Center, Carter Immunology Center, Department of Medicine, University of Virginia Health System, Charlottesville, Va
e Allergy and Immunology Section, Medical Service, Veterans Administration Medical Center, Tennessee Valley Healthcare System, Nashville, Tenn
f Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tenn
g Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tenn
h Institute for Immunology & Infectious Diseases, Murdoch University, Murdoch, Australia
| Supported by the Elizabeth and John Murray Endowment, Vanderbilt University. E.J.P. receives funding related to this project from the National Institutes of Health (NIH; 1P50GM115305-01, 1R01AI103348-01, and 1P30AI110527-01A1), National Health and Medical Research Foundation of Australia, and the Australian Centre for HIV and Hepatitis Virology Research. S.P.C. receives funding related to this project from NIH R56AI113095. |
|
| Disclosure of potential conflict of interest: C. A. Stone has received a grant from the National Institutes of Health (NIH; T32 HL87738), is employed by Vanderbilt University Medical Center, and has received travel support from the Young Investigators Respiratory Forum. S. P. Commins has received personal fees from Genentech and UpToDate and has received a grant from the NIH. E. J. Phillips has received grants from the NIH, the National Health Medical Research Council, and the Australian Centre for HIV/Hep Virology Research; has received royalties from UpToDate; has received consulting fees from Biocryst and Aicuris; and is codirector of IIID Pty Ltd that holds patent for HLA-B*57:01 testing. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2016
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 139 - N° 5
P. 1710 - mai 2017 Retour au numéro
Article précédent
- Liver transplantation in patients with primary antibody deficiency
- Silje F. Jørgensen, Magnhild E. Macpherson, Kristian Bjøro, Tom H. Karlsen, Henrik M. Reims, Krzysztof Grzyb, Bjarte Fosby, Børre Fevang, Pål Aukrust, Ingvild Nordøy
- Costs associated with treatment of severe combined immunodeficiency—rationale for newborn screening in Sweden
- Ann Gardulf, Jacek Winiarski, Moa Thorin, Marianne Heibert Arnlind, Ulrika von Döbeln, Lennart Hammarström
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?